Advertisement

ADVERTISEMENT

Waldenstrom Macroglobulinemia

News
Frontline Therapy With RCVP has Similar Outcomes to Bendamustine-Rituximab in Patients With Treatment-Naïve WM
01/05/2022
Data from a real-world population-based analysis of frontline therapy with bendamustine-rituximab in patients with TN WM were presented at the 2021 ASH Annual Meeting to evaluate outcomes in TN-WM patients comparing BR with the combination of...
Data from a real-world population-based analysis of frontline therapy with bendamustine-rituximab in patients with TN WM were presented at the 2021 ASH Annual Meeting to evaluate outcomes in TN-WM patients comparing BR with the combination of...
Data from a real-world...
01/05/2022
Oncology
medical
Test Your Knowledge
Quiz: What is the First FDA Approved Therapy for WM?
12/22/2021
True or false: Ibrutinib, a BTK inhibitor, is not the first FDA approved therapy for WM.
True or false: Ibrutinib, a BTK inhibitor, is not the first FDA approved therapy for WM.
True or false: Ibrutinib, a BTK...
12/22/2021
Oncology
Q mark
Test Your Knowledge
Quiz: Is ASCT a Feasible Treatment Option for Patients With WM?
12/22/2021
True or false: ASCT is a feasible treatment option for patients with relapsed WM.
True or false: ASCT is a feasible treatment option for patients with relapsed WM.
True or false: ASCT is a...
12/22/2021
Oncology
Dr Treon
Videos
Dr Treon Highlights Mavorixafor Plus Ibrutinib for Patients With WM
12/16/2021
Steven P. Treon, MD, MA, PhD, discusses preliminary clinical data from a phase 1b study of mavorixafor in combination with ibrutinib for patients with WM with MYDD88 and CXCR4 mutations. These data were presented at the 2021 ASH Annual...
Steven P. Treon, MD, MA, PhD, discusses preliminary clinical data from a phase 1b study of mavorixafor in combination with ibrutinib for patients with WM with MYDD88 and CXCR4 mutations. These data were presented at the 2021 ASH Annual...
Steven P. Treon, MD, MA, PhD,...
12/16/2021
Oncology
Test Your Knowledge
Quiz: Is This Triplet Combo Effective for R/R WM?
11/17/2021
True or false: When used a second-line therapy, bendamustine, rituximab, and bortezomib, is not an effective treatment for patients with R/R WM.
True or false: When used a second-line therapy, bendamustine, rituximab, and bortezomib, is not an effective treatment for patients with R/R WM.
True or false: When used a...
11/17/2021
Oncology
News
Triplet Therapy Found Effective, Well-Tolerated in R/R WM
11/17/2021
A phase 2 trial found that bendamustine, rituximab, and bortezomib, used a second-line therapy, is an effective and well-tolerated salvage treatment for patients with R/R WM; these data were presented at the 2021 ASH Annual Meeting.
A phase 2 trial found that bendamustine, rituximab, and bortezomib, used a second-line therapy, is an effective and well-tolerated salvage treatment for patients with R/R WM; these data were presented at the 2021 ASH Annual Meeting.
A phase 2 trial found that...
11/17/2021
Oncology
qqqq
Test Your Knowledge
Quiz: Which Treatment Shows Continued Efficacy in TN and R/R WM?
11/10/2021
Which treatment demonstrated sustained efficacy in TN and R/R WM after a 2-year follow-up period?
Which treatment demonstrated sustained efficacy in TN and R/R WM after a 2-year follow-up period?
Which treatment demonstrated...
11/10/2021
Oncology
News
Tirabrutinib Shows Continued Efficacy in TN, R/R WM
11/10/2021
A report on 2 years of follow-up data from a phase 2 study found tirabrutinib continued to show efficacy in patients with TN or R/R WM; these findings were presented at the 2021 Annual ASH Meeting.
A report on 2 years of follow-up data from a phase 2 study found tirabrutinib continued to show efficacy in patients with TN or R/R WM; these findings were presented at the 2021 Annual ASH Meeting.
A report on 2 years of follow-up...
11/10/2021
Oncology
Michael Wang, MD, Talks LOXO-305 for MCL, WM
Videos
Michael Wang, MD, Talks LOXO-305 for MCL, WM
12/07/2020
In this video, Dr Wang discusses the use of LOXO-305, a highly selective BTK inhibitor, in patients with pretreated MCL, WM, and other NHLs.
In this video, Dr Wang discusses the use of LOXO-305, a highly selective BTK inhibitor, in patients with pretreated MCL, WM, and other NHLs.
In this video, Dr Wang discusses...
12/07/2020
Oncology

Advertisement

Advertisement

Advertisement

Advertisement

Upcoming Events

November 23 ⁠–⁠ November 24
December 4 ⁠–⁠ December 5
Great Debates & Updates in Diabetic Foot
December 6 ⁠–⁠ December 7
AIBD logo
December 9 ⁠–⁠ December 11
December 9 ⁠–⁠ December 11
Psych Congress Primary Care Online Series
December 12 ⁠–⁠ December 13
December 14 ⁠–⁠ December 15
February 2 ⁠–⁠ February 5
Western AF Symposium
February 27 ⁠–⁠ March 1
DCLF
March 17 ⁠–⁠ March 19
See Full Calendar

Advertisement

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use